Cargando…

Interferon gamma-induced protein 10 (IP-10) for the early prognosis of the risk for severe respiratory failure and death in COVID-19 pneumonia

OBJECTIVES: Elevated concentrations of soluble urokinase plasminogen activator receptor (suPAR) predict progression to severe respiratory failure (SRF) or death among patients with COVID-19 pneumonia and guide early anakinra treatment. As suPAR testing may not be routinely available in every health-...

Descripción completa

Detalles Bibliográficos
Autores principales: Samaras, Charilaos, Kyriazopoulou, Evdoxia, Poulakou, Garyfallia, Reiner, Eran, Kosmidou, Maria, Karanika, Ioanna, Petrakis, Vasileios, Adamis, George, Gatselis, Nikolaos K., Fragkou, Archontoula, Rapti, Aggeliki, Taddei, Eleonora, Kalomenidis, Ioannis, Chrysos, George, Bertoli, Giulia, Kainis, Ilias, Alexiou, Zoi, Castelli, Francesco, Saverio Serino, Francesco, Bakakos, Petros, Nicastri, Emanuele, Tzavara, Vassiliki, Kostis, Evangelos, Dagna, Lorenzo, Koukidou, Sofia, Tzatzagou, Glykeria, Chini, Maria, Bassetti, Matteo, Trakatelli, Christina, Tsoukalas, George, Selmi, Carlo, Samarkos, Michael, Pyrpasopoulou, Athina, Masgala, Aikaterini, Antonakis, Emmanouil, Argyraki, Aikaterini, Akinosoglou, Karolina, Sympardi, Styliani, Panagopoulos, Periklis, Milionis, Haralampos, Metallidis, Simeon, Syrigos, Konstantinos N., Angel, Alon, Dalekos, George N., Netea, Mihai G., Giamarellos-Bourboulis, Evangelos J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747699/
https://www.ncbi.nlm.nih.gov/pubmed/36529030
http://dx.doi.org/10.1016/j.cyto.2022.156111
_version_ 1784849662396596224
author Samaras, Charilaos
Kyriazopoulou, Evdoxia
Poulakou, Garyfallia
Reiner, Eran
Kosmidou, Maria
Karanika, Ioanna
Petrakis, Vasileios
Adamis, George
Gatselis, Nikolaos K.
Fragkou, Archontoula
Rapti, Aggeliki
Taddei, Eleonora
Kalomenidis, Ioannis
Chrysos, George
Bertoli, Giulia
Kainis, Ilias
Alexiou, Zoi
Castelli, Francesco
Saverio Serino, Francesco
Bakakos, Petros
Nicastri, Emanuele
Tzavara, Vassiliki
Kostis, Evangelos
Dagna, Lorenzo
Koukidou, Sofia
Tzatzagou, Glykeria
Chini, Maria
Bassetti, Matteo
Trakatelli, Christina
Tsoukalas, George
Selmi, Carlo
Samarkos, Michael
Pyrpasopoulou, Athina
Masgala, Aikaterini
Antonakis, Emmanouil
Argyraki, Aikaterini
Akinosoglou, Karolina
Sympardi, Styliani
Panagopoulos, Periklis
Milionis, Haralampos
Metallidis, Simeon
Syrigos, Konstantinos N.
Angel, Alon
Dalekos, George N.
Netea, Mihai G.
Giamarellos-Bourboulis, Evangelos J.
author_facet Samaras, Charilaos
Kyriazopoulou, Evdoxia
Poulakou, Garyfallia
Reiner, Eran
Kosmidou, Maria
Karanika, Ioanna
Petrakis, Vasileios
Adamis, George
Gatselis, Nikolaos K.
Fragkou, Archontoula
Rapti, Aggeliki
Taddei, Eleonora
Kalomenidis, Ioannis
Chrysos, George
Bertoli, Giulia
Kainis, Ilias
Alexiou, Zoi
Castelli, Francesco
Saverio Serino, Francesco
Bakakos, Petros
Nicastri, Emanuele
Tzavara, Vassiliki
Kostis, Evangelos
Dagna, Lorenzo
Koukidou, Sofia
Tzatzagou, Glykeria
Chini, Maria
Bassetti, Matteo
Trakatelli, Christina
Tsoukalas, George
Selmi, Carlo
Samarkos, Michael
Pyrpasopoulou, Athina
Masgala, Aikaterini
Antonakis, Emmanouil
Argyraki, Aikaterini
Akinosoglou, Karolina
Sympardi, Styliani
Panagopoulos, Periklis
Milionis, Haralampos
Metallidis, Simeon
Syrigos, Konstantinos N.
Angel, Alon
Dalekos, George N.
Netea, Mihai G.
Giamarellos-Bourboulis, Evangelos J.
author_sort Samaras, Charilaos
collection PubMed
description OBJECTIVES: Elevated concentrations of soluble urokinase plasminogen activator receptor (suPAR) predict progression to severe respiratory failure (SRF) or death among patients with COVID-19 pneumonia and guide early anakinra treatment. As suPAR testing may not be routinely available in every health-care setting, alternative biomarkers are needed. We investigated the performance of C-reactive protein (CRP), interferon gamma-induced protein-10 (IP-10) and TNF-related apoptosis-inducing ligand (TRAIL) for predicting SRF or death in COVID-19. METHODS: Two cohorts were studied; one discovery cohort with 534 patients from the SAVE-MORE clinical trial; and one validation cohort with 364 patients from the SAVE trial including also 145 comparators. CRP, IP-10 and TRAIL were measured by the MeMed Key® platform in order to select the biomarker with the best prognostic performance for the early prediction of progression into SRF or death. RESULTS: IP-10 had the best prognostic performance: baseline concentrations 2000 pg/ml or higher predicted equally well to suPAR (sensitivity 85.0 %; negative predictive value 96.6 %). Odds ratio for poor outcome among anakinra-treated participants of the SAVE-MORE trial was 0.35 compared to placebo when IP-10 was 2,000 pg/ml or more. IP-10 could divide different strata of severity for SRF/death by day 14 in the validation cohort. Anakinra treatment decreased this risk irrespective the IP-10 concentrations. CONCLUSIONS: IP-10 concentrations of 2,000 pg/ml or higher are a valid alternative to suPAR for the early prediction of progression into SRF or death the first 14 days from hospital admission for COVID-19 and they may guide anakinra treatment. Trial registration. ClinicalTrials.gov, NCT04680949 and NCT04357366.
format Online
Article
Text
id pubmed-9747699
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The Author(s). Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-97476992022-12-14 Interferon gamma-induced protein 10 (IP-10) for the early prognosis of the risk for severe respiratory failure and death in COVID-19 pneumonia Samaras, Charilaos Kyriazopoulou, Evdoxia Poulakou, Garyfallia Reiner, Eran Kosmidou, Maria Karanika, Ioanna Petrakis, Vasileios Adamis, George Gatselis, Nikolaos K. Fragkou, Archontoula Rapti, Aggeliki Taddei, Eleonora Kalomenidis, Ioannis Chrysos, George Bertoli, Giulia Kainis, Ilias Alexiou, Zoi Castelli, Francesco Saverio Serino, Francesco Bakakos, Petros Nicastri, Emanuele Tzavara, Vassiliki Kostis, Evangelos Dagna, Lorenzo Koukidou, Sofia Tzatzagou, Glykeria Chini, Maria Bassetti, Matteo Trakatelli, Christina Tsoukalas, George Selmi, Carlo Samarkos, Michael Pyrpasopoulou, Athina Masgala, Aikaterini Antonakis, Emmanouil Argyraki, Aikaterini Akinosoglou, Karolina Sympardi, Styliani Panagopoulos, Periklis Milionis, Haralampos Metallidis, Simeon Syrigos, Konstantinos N. Angel, Alon Dalekos, George N. Netea, Mihai G. Giamarellos-Bourboulis, Evangelos J. Cytokine Article OBJECTIVES: Elevated concentrations of soluble urokinase plasminogen activator receptor (suPAR) predict progression to severe respiratory failure (SRF) or death among patients with COVID-19 pneumonia and guide early anakinra treatment. As suPAR testing may not be routinely available in every health-care setting, alternative biomarkers are needed. We investigated the performance of C-reactive protein (CRP), interferon gamma-induced protein-10 (IP-10) and TNF-related apoptosis-inducing ligand (TRAIL) for predicting SRF or death in COVID-19. METHODS: Two cohorts were studied; one discovery cohort with 534 patients from the SAVE-MORE clinical trial; and one validation cohort with 364 patients from the SAVE trial including also 145 comparators. CRP, IP-10 and TRAIL were measured by the MeMed Key® platform in order to select the biomarker with the best prognostic performance for the early prediction of progression into SRF or death. RESULTS: IP-10 had the best prognostic performance: baseline concentrations 2000 pg/ml or higher predicted equally well to suPAR (sensitivity 85.0 %; negative predictive value 96.6 %). Odds ratio for poor outcome among anakinra-treated participants of the SAVE-MORE trial was 0.35 compared to placebo when IP-10 was 2,000 pg/ml or more. IP-10 could divide different strata of severity for SRF/death by day 14 in the validation cohort. Anakinra treatment decreased this risk irrespective the IP-10 concentrations. CONCLUSIONS: IP-10 concentrations of 2,000 pg/ml or higher are a valid alternative to suPAR for the early prediction of progression into SRF or death the first 14 days from hospital admission for COVID-19 and they may guide anakinra treatment. Trial registration. ClinicalTrials.gov, NCT04680949 and NCT04357366. The Author(s). Published by Elsevier Ltd. 2023-02 2022-12-14 /pmc/articles/PMC9747699/ /pubmed/36529030 http://dx.doi.org/10.1016/j.cyto.2022.156111 Text en © 2022 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Samaras, Charilaos
Kyriazopoulou, Evdoxia
Poulakou, Garyfallia
Reiner, Eran
Kosmidou, Maria
Karanika, Ioanna
Petrakis, Vasileios
Adamis, George
Gatselis, Nikolaos K.
Fragkou, Archontoula
Rapti, Aggeliki
Taddei, Eleonora
Kalomenidis, Ioannis
Chrysos, George
Bertoli, Giulia
Kainis, Ilias
Alexiou, Zoi
Castelli, Francesco
Saverio Serino, Francesco
Bakakos, Petros
Nicastri, Emanuele
Tzavara, Vassiliki
Kostis, Evangelos
Dagna, Lorenzo
Koukidou, Sofia
Tzatzagou, Glykeria
Chini, Maria
Bassetti, Matteo
Trakatelli, Christina
Tsoukalas, George
Selmi, Carlo
Samarkos, Michael
Pyrpasopoulou, Athina
Masgala, Aikaterini
Antonakis, Emmanouil
Argyraki, Aikaterini
Akinosoglou, Karolina
Sympardi, Styliani
Panagopoulos, Periklis
Milionis, Haralampos
Metallidis, Simeon
Syrigos, Konstantinos N.
Angel, Alon
Dalekos, George N.
Netea, Mihai G.
Giamarellos-Bourboulis, Evangelos J.
Interferon gamma-induced protein 10 (IP-10) for the early prognosis of the risk for severe respiratory failure and death in COVID-19 pneumonia
title Interferon gamma-induced protein 10 (IP-10) for the early prognosis of the risk for severe respiratory failure and death in COVID-19 pneumonia
title_full Interferon gamma-induced protein 10 (IP-10) for the early prognosis of the risk for severe respiratory failure and death in COVID-19 pneumonia
title_fullStr Interferon gamma-induced protein 10 (IP-10) for the early prognosis of the risk for severe respiratory failure and death in COVID-19 pneumonia
title_full_unstemmed Interferon gamma-induced protein 10 (IP-10) for the early prognosis of the risk for severe respiratory failure and death in COVID-19 pneumonia
title_short Interferon gamma-induced protein 10 (IP-10) for the early prognosis of the risk for severe respiratory failure and death in COVID-19 pneumonia
title_sort interferon gamma-induced protein 10 (ip-10) for the early prognosis of the risk for severe respiratory failure and death in covid-19 pneumonia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747699/
https://www.ncbi.nlm.nih.gov/pubmed/36529030
http://dx.doi.org/10.1016/j.cyto.2022.156111
work_keys_str_mv AT samarascharilaos interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia
AT kyriazopoulouevdoxia interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia
AT poulakougaryfallia interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia
AT reinereran interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia
AT kosmidoumaria interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia
AT karanikaioanna interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia
AT petrakisvasileios interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia
AT adamisgeorge interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia
AT gatselisnikolaosk interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia
AT fragkouarchontoula interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia
AT raptiaggeliki interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia
AT taddeieleonora interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia
AT kalomenidisioannis interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia
AT chrysosgeorge interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia
AT bertoligiulia interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia
AT kainisilias interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia
AT alexiouzoi interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia
AT castellifrancesco interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia
AT saverioserinofrancesco interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia
AT bakakospetros interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia
AT nicastriemanuele interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia
AT tzavaravassiliki interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia
AT kostisevangelos interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia
AT dagnalorenzo interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia
AT koukidousofia interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia
AT tzatzagouglykeria interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia
AT chinimaria interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia
AT bassettimatteo interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia
AT trakatellichristina interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia
AT tsoukalasgeorge interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia
AT selmicarlo interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia
AT samarkosmichael interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia
AT pyrpasopoulouathina interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia
AT masgalaaikaterini interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia
AT antonakisemmanouil interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia
AT argyrakiaikaterini interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia
AT akinosogloukarolina interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia
AT sympardistyliani interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia
AT panagopoulosperiklis interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia
AT milionisharalampos interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia
AT metallidissimeon interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia
AT syrigoskonstantinosn interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia
AT angelalon interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia
AT dalekosgeorgen interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia
AT neteamihaig interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia
AT giamarellosbourboulisevangelosj interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia